TY - JOUR AU - Velez, Maria A. AU - Burns, Timothy F. PY - 2019 TI - Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer? JF - Translational Lung Cancer Research; Vol 8, Supplement 4 (December 31, 2019): Translational Lung Cancer Research Y2 - 2019 KW - N2 - The immune checkpoint inhibitor pembrolizumab, has been shown to be efficacious and to have significant and durable antitumor activity in a subset of patients with advanced non-small cell lung cancer (NSCLC). Most notably in NSCLC with high expression of the programmed death ligand-1 (PD-L1). Similarly, there is abundant data to support the use of epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line therapy in patients whose tumors harbor EGFR mutations (1). UR - https://tlcr.amegroups.org/article/view/28523